[go: up one dir, main page]

NZ335922A - Use of leukotriene antagonists for treating squamous cell carcinoma (cancer) - Google Patents

Use of leukotriene antagonists for treating squamous cell carcinoma (cancer)

Info

Publication number
NZ335922A
NZ335922A NZ335922A NZ33592297A NZ335922A NZ 335922 A NZ335922 A NZ 335922A NZ 335922 A NZ335922 A NZ 335922A NZ 33592297 A NZ33592297 A NZ 33592297A NZ 335922 A NZ335922 A NZ 335922A
Authority
NZ
New Zealand
Prior art keywords
alkyl
bond
halo
hydrogen
independently
Prior art date
Application number
NZ335922A
Inventor
Jerome H Fleisch
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ335922A publication Critical patent/NZ335922A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is the use of the above compound, having activity as a leukotriene B4 antagonist, for the treatment or inhibition of oral squamous cell carcinoma. Treatment involves administering to a mammal in need thereof an effective amount of a compound of the formula I wherein: R1 is C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C1-C4 alkoxy, (C1-C4 alkyl)thio, halo, or R2-substituted phenyl; R2 and R3 are each independently hydrogen, halo, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, (C1-C4 alkyl)-S(O)q-, trifluoromethyl, or di-(C1-C3alkyl)amino; X is -O-, -S-, -C(=O), or -CH2-; Y is -O- or -CH2-, or when taken together, -X-Y- is -CH=CH- or -C=C-; Z is a straight or branched chain C1-C10 alkylidenyl; A is a bond, -0-, -S-, -CH=CH-, or -CRaRb-, where Ra and Rb are each independently hydrogen, C1-C5 alkyl, or R7-substituted phenyl, or when taken together with the carbon atom to which they are attached, form a C4-C8 cycloalkyl ring; R4 is R6, or figure Ia, Ib, Ic, Id, Ie or If' where, R6 is independently -COOH, 5-tetrazolyl, -CON(R9)2, or -CONHSO2Rl0; R7 is hydrogen, Cl-C4 alkyl, C2-Cs alkenyl, C2-C5 alkynyl, benzyl, methoxy, -W-R6, -T-G-R6, (C1-C4 alkyl)-T-(C1-C4 alkylidenyl)-O-, or hydroxy; R8 is hydrogen or halo; R9 is independently hydrogen, phenyl, or C1-C4 alkyl, or when taken together with the nitrogen atom form a morpholino, piperidino, piperazino, or pyrrolidino group; R10 is C1-C4 alkyl or phenyl; R11 is R2, -W-R6, or -T-G-R6; W is a bond or straight or branched chain divalent hydrocarbyl radical of one to eight carbon atoms; G is a straight or branched chain divalent hydrocarbyl radical of one to eight carbon atoms; T is a bond, -CH2-, -O-, -NH-, -NHCO-, -C(=O)-, or -S(O)q"-; K is -C(=O)- or -CH(OH)-; q is independently 0, 1, or 2; p is 0 or 1; t is 0 or 1; provided when X is -O- or -S-, Y is not -O-; provided when A is -O- or -S-, R4 is not R6; provided when A is -O- or -S- and Z is a bond, Y is not -0-; provided W is not a bond when p is 0;
NZ335922A 1996-12-13 1997-12-02 Use of leukotriene antagonists for treating squamous cell carcinoma (cancer) NZ335922A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3426996P 1996-12-13 1996-12-13
US4087497P 1997-03-21 1997-03-21
PCT/US1997/021953 WO1998025615A1 (en) 1996-12-13 1997-12-02 Leukotriene antagonists for oral squamous cell carcinoma

Publications (1)

Publication Number Publication Date
NZ335922A true NZ335922A (en) 2000-12-22

Family

ID=26710754

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335922A NZ335922A (en) 1996-12-13 1997-12-02 Use of leukotriene antagonists for treating squamous cell carcinoma (cancer)

Country Status (14)

Country Link
EP (1) EP0964683A4 (en)
JP (1) JP2001509142A (en)
KR (1) KR20000069452A (en)
CN (1) CN1245429A (en)
AU (1) AU726215B2 (en)
CA (1) CA2274855A1 (en)
EA (1) EA002742B1 (en)
IL (1) IL130304A0 (en)
NO (1) NO992846L (en)
NZ (1) NZ335922A (en)
PL (1) PL334241A1 (en)
TR (1) TR199901307T2 (en)
UA (1) UA47505C2 (en)
WO (1) WO1998025615A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
KR101898879B1 (en) 2014-03-05 2018-09-14 재단법인 진안홍삼연구소 A composition comprising the red ginseng extract of postmanufacture for treating or preventing oral squamous cell carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372648A (en) * 1986-09-16 1988-04-02 Sumitomo Pharmaceut Co Ltd Novel unsaturated fatty acid derivative
CZ276694A3 (en) * 1991-11-25 1995-11-15 Lilly Co Eli Process for preparing diphenyl derivative
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists

Also Published As

Publication number Publication date
AU7845198A (en) 1998-07-03
UA47505C2 (en) 2002-07-15
EA002742B1 (en) 2002-08-29
KR20000069452A (en) 2000-11-25
EP0964683A4 (en) 2002-08-14
WO1998025615A1 (en) 1998-06-18
IL130304A0 (en) 2000-06-01
AU726215B2 (en) 2000-11-02
NO992846D0 (en) 1999-06-11
CA2274855A1 (en) 1998-06-18
NO992846L (en) 1999-06-11
CN1245429A (en) 2000-02-23
EA199900543A1 (en) 2000-02-28
TR199901307T2 (en) 1999-08-23
PL334241A1 (en) 2000-02-14
JP2001509142A (en) 2001-07-10
EP0964683A1 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
ZA948026B (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
DE69923849D1 (en) QUINOLIN-2-ON DERIVATIVES USE AS ANTICROPHOSIS
CA2280850A1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
ES8404990A1 (en) Anti-hypertensive prolinol-based peptides.
HUP0103386A2 (en) Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
NZ333315A (en) Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions
DE69132713D1 (en) Benzylidenthiazolidine derivatives, their preparation and their use as lipid peroxide inhibitors
NZ335922A (en) Use of leukotriene antagonists for treating squamous cell carcinoma (cancer)
NZ514542A (en) Vasopressin antagonists for the treatment of pulmonary hypertension
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
MY121623A (en) Methods of preventing breast cancer.
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
PT986393E (en) USING A NITROXIDE OR ITS PRO-PHARMACY IN THE CANCER'S PROFILACTIC AND THERAPEUTIC TREATMENT
IL114951A0 (en) Quinozolinone-containing pharmaceutical compositions for prevention of neovascularization
Edmonson et al. Phase II Study of Recombinant Alfa-2a Interferon in Patients With Advanced Bone
NZ332348A (en) use of triphenylethylene derivatives as antioxidant agents
NZ332687A (en) use of 1-methyl-carbapenem derivatives as anti-helicobacter pylori agents
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
NZ333587A (en) Topiramate derivatives useful in treating psoriasis
ES8707939A1 (en) N-carboxyalcoyl-2-oxo-3-diaryl-5,6-triazines useful as therapeutic agents.
MXPA02001104A (en) NEW CYTOTOXIC PYRIDO[2,3,4kl]ACRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
PL324086A1 (en) Antagonists of calcium passages
Salomaa et al. Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)